On January 05, 2024, the U.S. Food and Drug Administration (FDA) released several announcements regarding safety concerns and upcoming events.

Safety Communication Regarding Synovo Total Hip System

The FDA cautioned healthcare providers against using the Total Hip System, including resurfacing implants, produced by Synovo Production, Inc. The agency highlighted the lack of established safety and effectiveness for these devices manufactured by Synovo after 2019.

Safety Alert for Tejocote Root Supplements

Another safety alert was issued, this time concerning certain tejocote root supplements that were found to be substituted with toxic yellow oleander. The FDA urged caution regarding the consumption of such products.

Upcoming Workshop on Psychedelic Clinical Study Design

Scheduled for January 31 and February 1, the Reagan-Udall Foundation for the FDA will host a virtual public workshop titled “Advancing Psychedelic Clinical Study Design.” This event aims to gather researchers, regulated industry representatives, and stakeholders to discuss scientific challenges in psychedelic clinical trials and drug development. Following the FDA's issuance of the first draft guidance for industry on psychedelic drugs in June 2023, titled "Psychedelic Drugs: Considerations for Clinical Investigations," the workshop will focus on understanding scientists' experiences, exploring trial design considerations, and discussing current research perspectives in psychedelic clinical trials.

Highlights

• FDA warns against using Synovo Total Hip System manufactured after 2019 due to lack of established safety and effectiveness.
• Safety alert issued for certain tejocote root supplements containing toxic yellow oleander.
• Workshop on Psychedelic Clinical Study Design to address scientific challenges in clinical trials and drug development for psychedelic drugs.